Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Stanford University
This PHASE2 trial investigates KRAS Gene Mutation and Metastatic Malignant Neoplasm in the Brain and is currently completed. Stanford University leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Nov 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jul 2020 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
May 2019 — Dec 2019 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Sep 2018 — May 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .